Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry
Open Access
- 17 June 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal – Cardiovascular Imaging
- Vol. 15 (11), 1246-1255
- https://doi.org/10.1093/ehjci/jeu114
Abstract
The aim of this study was to evaluate the association of baseline tricuspid regurgitation (TR) on the outcomes after percutaneous mitral valve repair (PMVR) with the MitraClip system. Data from 146 consecutive patients with functional mitral regurgitation (MR) were obtained. Two different groups, dichotomized according to the degree of pre-procedural TR (moderate/severe, n = 47 and none/mild, n = 99), had their clinical and echocardiographic outcomes through 12-month compared. At 30-day, the primary safety endpoint was significantly higher in moderate/severe TR compared with none/mild TR (10.6 vs. 2.0%, P = 0.035). Marked reduction in MR grades observed post-procedure were maintained through 12 months. Although NYHA functional class significantly improved in both groups compared with baseline, it was impaired in moderate/severe TR compared with the none/mild TR group (NYHA > II at 30 day: 33.3 vs. 9.2%, P < 0.001; at 1 year: 38.5 vs. 12.3%, respectively, P = 0.006). Left ventricle reverse remodelling and ejection fraction improvement were revealed in both groups. The primary efficacy endpoint at 12-month determined by freedom from death, surgery for mitral valve dysfunction, or grade ≥3+ MR was comparable between groups, but combined death and re-hospitalization for heart failure rates were higher in the moderate/severe TR group. Multivariable Cox regression analysis demonstrated that baseline moderate/severe TR and chronic kidney disease were independent predictors of this combined endpoint. Although PMVR with MitraClip led to improvement in MR, TR, and NYHA functional class in patients with baseline moderate/severe TR, the primary safety endpoint at 30-day was impaired, while moderate/severe TR independently predicted death and re-hospitalization for heart failure at 12-month.Keywords
This publication has 34 references indexed in Scilit:
- Prevalence and Outcomes of Unoperated Patients With Severe Symptomatic Mitral Regurgitation and Heart FailureJournal of the American College of Cardiology, 2014
- Relationship Between the Magnitude of Reduction in Mitral Regurgitation Severity and Left Ventricular and Left Atrial Reverse Remodeling After MitraClip TherapyCirculation, 2013
- Guidelines on the management of valvular heart disease (version 2012)European Heart Journal, 2012
- Echocardiographic-based treatment of functional tricuspid regurgitationThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Percutaneous Repair or Surgery for Mitral RegurgitationThe New England Journal of Medicine, 2011
- Percutaneous mitral valve repair with the MitraClip system: acute results from a real world settingEuropean Heart Journal, 2010
- Acute outcomes of MitraClip therapy for mitral regurgitation in high-surgical-risk patients: emphasis on adverse valve morphology and severe left ventricular dysfunctionEuropean Heart Journal, 2010
- Long‐term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunctionEuropean Journal of Heart Failure, 2009
- Impact of Mitral Valve Annuloplasty Combined With Revascularization in Patients With Functional Ischemic Mitral RegurgitationJournal of the American College of Cardiology, 2007
- Natural history of the asymptomatic/minimally symptomatic patient with severe mitral regurgitation secondary to mitral valve prolapse and normal right and left ventricular performanceThe American Journal of Cardiology, 1994